Posted by ABMN Staff on May 15th, 2024
Insmed (NASDAQ:INSM – Get Free Report) had its target price increased by research analysts at Mizuho from $35.00 to $36.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “buy”...
More of this article »